Home
Drugs
Ipilimumab
Clinical Trials

Clinical Trials Related to Ipilimumab

Related studies linked through entity extraction aliases.

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Status: RECRUITING
Phase: PHASE2

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

Status: RECRUITING
Phase: PHASE1

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

Status: RECRUITING
Phase: PHASE1/PHASE2

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2

Status: TERMINATED
Phase: PHASE2

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

Status: RECRUITING
Phase: PHASE2

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Status: RECRUITING
Phase: PHASE3

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Status: RECRUITING
Phase: PHASE2

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

Status: RECRUITING
Phase: PHASE2

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

Status: NOT_YET_RECRUITING
Phase: PHASE1/PHASE2

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

Status: RECRUITING
Phase: PHASE2

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Status: RECRUITING
Phase: PHASE2/PHASE3

Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

MAQ-001 in Patients With Advanced Solid Tumors

Status: RECRUITING
Phase: PHASE1

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Status: RECRUITING
Phase: PHASE1

The Sagittarius Trial

Status: RECRUITING
Phase: PHASE3

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Status: WITHDRAWN
Phase: PHASE2

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Status: RECRUITING
Phase: PHASE1

Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer

Status: TERMINATED
Phase: PHASE1/PHASE2

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

Status: RECRUITING
Phase: PHASE1